M&A Deal Summary

Takeda Acquires TiGenix N.V.

On July 31, 2018, Takeda acquired life science company TiGenix N.V.

Acquisition Highlights
  • This is Takeda’s 11th transaction in the Life Science sector.
  • This is Takeda’s 1st transaction in Belgium.

M&A Deal Summary
Date 2018-07-31
Target TiGenix N.V.
Sector Life Science
Buyer(s) Takeda
Deal Type Add-on Acquisition

Target

TiGenix N.V.

Leuven, Belgium
TiGenix N.V. is a European cell therapy company with a proprietary validated allogeneic expanded adipose-derived stem cell (eASC) platform technology for the treatment of autoimmune and inflammatory diseases, and a commercialized product. TiGenix was formed in 2000 and is based in Leuven, Belgium.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Takeda

Tokyo, Japan
Category Company
Founded 1781
Sector Life Science
Employees47,347
Revenue 4.03T JPY (2023)
DESCRIPTION
Takeda's corporate headquarters in Tokyo, Japan.
Takeda's corporate headquarters in Tokyo, Japan.

Takeda is a global biopharmaceutical organization committed to improving the health and well-being of people worldwide. Takeda is dedicated to addressing unmet medical needs through the development of innovative and transformative therapies. The Company's diverse portfolio encompasses a wide range of therapeutic areas, including oncology, gastroenterology, rare diseases, neuroscience, and vaccines. Takeda was originally established in 1781 and is based in Tokyo, Japan.

DEAL STATS #
Overall 12 of 18
Sector (Life Science) 11 of 17
Type (Add-on Acquisition) 11 of 15
Country (Belgium) 1 of 1
Year (2018) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-05-08 Shire

Dublin, Ireland

Shire plc is a global specialty biopharmaceutical company. Shire plc strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.

Buy £44.0B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-05-09 Xiidra

Basel, Switzerland

XIIDRA (lifitegrast ophthalmic solution) 5% is a prescription eye drop used to treat the signs and symptoms of dry eye disease. Xiidra is based in Basel, Switzerland.

Sell -
Mergr

Product

Company

Legal